Non-invasive brain stimulation for mild cognitive impairment in Parkinson's disease
Official title: NEuroStimulation for the Treatment of Mild Cognitive Impairment in Parkinson's Disease: an Acceptability Cross-over Study
Run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · NCT06399731 · Data updated 2026-11-12
This study is testing two non-invasive brain stimulation methods to see if they can help people with Parkinson's disease who have mild cognitive impairment feel better and improve their thinking skills.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Academic / other |
| Locations | 1 site (Amsterdam, North Holland) |
| Status | Recruiting |
| Started | May 31, 2024 |
| Main results expected | January 1, 2027 |
| Study ends | April 1, 2027 |
| Registry record updated | October 29, 2026 |
| Trial ID | NCT06399731 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals diagnosed with Parkinson's disease who exhibit mild to moderate cognitive impairment.
✕Probably not a fit
Patients with severe depressive disorders or indications of dementia may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study investigates the acceptability of two non-invasive brain stimulation methods, repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), for treating mild cognitive impairment in individuals with Parkinson's disease. Twenty participants will undergo both interventions in a cross-over design, with each phase lasting four weeks, including a no-intervention baseline. The primary focus is on the acceptability of these interventions, while secondary outcomes will assess feasibility, cognitive function, neuropsychiatric symptoms, and motor function. MRI will be utilized to explore personalized targeting of the interventions.
Why it matters
Potential benefit: If successful, this approach could provide a new non-pharmacological treatment option for improving cognitive function in patients with Parkinson's disease.
How similar studies have gone: Previous studies have shown promise in using non-invasive brain stimulation techniques for cognitive impairment, but this specific approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of Parkinson's disease, diagnosed by a neurologist; * Mild to moderate disease stage (Hoehn \& Yahr disease stage \< 4); * Movement Disorders Society level I criteria for PD-MCI (Litvan et al., 2012): * Montreal Cognitive Assessment score range \[21-25\] (Dalrymple-Alford et al., 2010), or * performance 1-2 SD below appropriate norms on at least 2 neuropsychological tests, or * classification of PD-MCI based on recent (\< 6 months previous to participation) neuropsychological assessment taken elsewhere (report will be requested);- In case of (dopaminergic) medication use, participants are on stable medication for at least one month before participation and expect to remain on stable medication during the study Exclusion Criteria: * Indication for dementia based on the SAGE (cut-off ≤ 14; Scharre et al., 2010); * Severe depressive disorder (Beck Depression Inventory - Ib score \> 18); * Psychotic disorder (except for benign hallucinations with insight), screened with the Scale for Assessment of Positive Symptoms for Parkinson's disease; * Indication of alcohol or drug abuse; * Contra-indication for rTMS according to Magstim Rapid2 Manual; rTMS should not be: * used on or in the vicinity of patients or users with cardiac demand pacemakers, implanted medication pumps, cochlear devices, implanted defibrillators and/or implanted neurostimulators * used on or in the vicinity of patients with implanted metal objects• used on patients where the skin in the area to be contacted is broken * used on those with large ischaemic scars * used on pregnant women * used on infants under the age of 2 years * used on epileptic individuals * used on those with a family history of convulsions * used on individuals with brain lesions that could affect seizure threshold * used on individuals suffering from multiple sclerosis * used on individuals taking tricyclic antidepressants, neuroleptic agents or any other drug that could lower seizure threshold, * used on individuals suffering from sleep deprivation during rTMS procedures * used on individuals with a heavy consumption of alcohol or those using epileptogenic drugs * used on individuals with severe heart disease or with increased intracranial pressure be used on those who have uncontrolled migraines * Contra-indication for tDCS according to Neuroelectrics Starstim Manual; tDCS should not be used in case of: * Patients with a history of seizures; * Patients with unexplained episodes of loss of consciousness, since such condition could be related with brain alterations or epilepsy; * Patients with unstable or non-controlled neuropsychiatric illness; * Patients having implanted brain medical devices; * Patients with implanted pacemakers; * Patients having any electrically, magnetically or mechanically activated implant; * Patients having cardiac, neural or medication implants; * Patients having vascular clips or any other electrically sensitive support system in the brain; * Patients with serious brain injury; * Patients showing damage of skin at sites of stimulation (the device can only be used in healthy skin without wounds, otherwise the resistance to current can be altered); * Patients suffering from skin problems, such as dermatitis, psoriasis or eczema; * Patients suffering from severe or frequent headaches; * Patients with any serious life-threatening disease such as congestive heart failure, pulmonary obstructive chronic disease or active neoplasia; * Pregnant women (women of childbearing age should undertake a pregnancy test to confirm eligibility before treatment). * Contra-indication for MR imaging: * metal in the body (pacemaker, port-a-cath, prosthesis, (cochlear) implant) * previous brain surgery * head trauma that resulted in unconsciousness for at least 1 hour * clips * (old metal containing) tattoo * irremovable piercings * irremovable metal braces * pregnancy * claustrophobia other problems lying still for 45 minutes * metal in the teeth * neurostimulator (including deep brain stimulation) * Space-occupying lesion on MRI.
Where it's running
-
Amsterdam UMC
Amsterdam, North Holland, Netherlands Recruiting
Study contacts
- Study coordinator: Tim D van Balkom, PhD
- Email: t.vanbalkom@amsterdamumc.nl
- Phone: +31204441162
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
Parietal brain stimulation for memory in Parkinson’s with mild cognitive impairment
This study tests whether a short, high-dose burst of brain stimulation to the right superior parietal area can safely and feasibly help people with Parkinson’s-related cognitive impairment.
-
Using a VR app to improve cognitive skills in patients with mild cognitive impairment
This study is testing if a virtual reality app can help improve thinking and social skills in people with mild cognitive impairment compared to regular therapy.
-
Predicting disease progression in dementia using biomarkers and modeling
This study is trying to create a tool that helps predict how dementia will progress in people with mild cognitive impairment and different types of dementia, like Alzheimer's and Lewy Body Disease, by looking at brain scans, body fluids, and mental tests.
-
Understanding inflammation in Parkinson's and Alzheimer's diseases
This study is trying to understand how inflammation affects people with Parkinson's and Alzheimer's diseases by looking at their immune responses and comparing them to healthy individuals.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.